2014
DOI: 10.1200/jco.2014.32.15_suppl.e22091
|View full text |Cite
|
Sign up to set email alerts
|

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

11
99
1
1

Year Published

2015
2015
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 87 publications
(112 citation statements)
references
References 0 publications
11
99
1
1
Order By: Relevance
“…The overexpression of PD-L1 has been evaluated in different tumor entities such as breast cancer [25], lung cancer [26], renal and bladder cancer [27,28], and cutaneous malignant melanoma [24,[29][30][31][32]. With respect to our control group of cutaneous melanoma, our findings are in line with the literature, where the overexpression of PD-L1 in this tumor entity varies between 40 and 100%.…”
Section: Discussionsupporting
confidence: 87%
“…The overexpression of PD-L1 has been evaluated in different tumor entities such as breast cancer [25], lung cancer [26], renal and bladder cancer [27,28], and cutaneous malignant melanoma [24,[29][30][31][32]. With respect to our control group of cutaneous melanoma, our findings are in line with the literature, where the overexpression of PD-L1 in this tumor entity varies between 40 and 100%.…”
Section: Discussionsupporting
confidence: 87%
“…This is consistent with another report that interferon-g from lymphocytes induces PD-L1 expression and promotes the progression of ovarian cancer [32]. Simultaneous expression of PD-1 in TILs and PD-L1 by tumor cells is observed in 36% of ovarian cancers [15]. These observations together suggest that disrupting PD-1 signaling may reinvigorate ovarian tumor immunity and improve clinical outcomes.…”
Section: Programmed Cell Death-1 Pathway In Ovarian Cancersupporting
confidence: 92%
“…Another analysis of 870 whole tumors showed that 21.7% of breast cancers showed PD-L1 positivity on the tumor cells, and that this correlated with worse prognosis [13]. In addition, analysis of whole sections has shown that 20-45% of breast cancers expressed PD-L1 on tumor cells, with the highest expression on TNBC [4,14,15], and correlates with TILs and response to neoadjuvant chemotherapy [16].…”
Section: Programmed Cell Death-1 Pathway In Breast Cancermentioning
confidence: 99%
“…PD-1 is a receptor expressed on the surface of T cells that regulates the activation of T cells; PD-L1, the ligand of PD-1, is expressed in many cancers, including NSCLC, and is believed to promote evasion of the antitumor immune response at the tumor site 4,6,7 . Recently, antibodies that target PD-L1 or PD-1 have been developed for anticancer therapy in various types of cancers 8,9 and have been shown to be efficacious in the treatment of NSCLC M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 impact of PD-L1 protein expression have not been elucidated. Some recent studies have demonstrated that high expression of PD-L1 protein is associated with the presence of EGFR mutations and that mutated EGFR upregulates PD-L1 by activating downstream signaling pathways in NSCLC [13][14][15] .…”
Section: Introductionmentioning
confidence: 99%